Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities

1. Acquisition Details: Agilent Technologies has signed a definitive agreement to acquire Biovectra, a Canadian specialty CDMO, for $925 million through a mix of cash and debt financing.
2. Enhancing Capabilities: The acquisition aims to boost Agilent's biologics and CRISPR capabilities, leveraging Biovectra's state-of-the-art facilities for production and development.
3. Strategic Expansion: This deal marks Agilent's strategic expansion into the biologics and CRISPR space, enhancing its offerings in the life sciences sector.